EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME

Dual antiplatelet therapy, including clopidogrel and aspirin, in a significant share of patients after acute coronary syndrome (ACS) is characterized by high level of platelet reactivity, which is associated with an increased incidence of cardiovascular events. Perhaps it will make reasonable the prescription of new antiplatelet drugs, particularly the combination of ticagrelor with aspirin.

Aim. To assess the cost-effectiveness of VerifyNow P2Y12 platelet reactivity testing in patients after ACS.

Material and methods. The analysis was performed for patients aged 55 years after ACS by modeling based on the results of the PLATO trial considering Russian epidemiological data. The time horizon of simulation was 5 years. It was assumed that the patients were receiving either generic clopidogrel or ticagrelor for 1 year, or before maintenance treatment VerifyNow P2Y12 assay had been performed, and the patients with platelet reactivity index >230 24-48 hours after ACS were receiving ticagrelor and the remaining patients - generic clopidogrel. It was expected that after 1 year the patients would discontinue treatment with clopidogrel or ticagrelor, and hereafter additional therapeutic effect of their use would be absent. The costs of antiplatelet agents in the reference case corresponded to the weighted average price of public procurement in 2013 in Russia. The costs of treatment of complications corresponded to the compulsory health insurance rates for St. Petersburg in 2014. The cost and life expectancy were discounted at 3.5% per year.

Results. The platelet reactivity test and the prescription by its results of the combination of clopidogrel plus aspirin or ticagrelor plus aspirin can prevent 5 myocardial infarction and 6 deaths per 1000 patients additionally as compared with the prescription of clopidogrel plus aspirin combination to all patients. The costs for one additional year of life as compared with the combination of clopidogrel plus aspirin were 376.5 and 373.2 thousand rubles, respectively, the costs for one additional quality adjusted life year (QALY) were 433.8 and 509.8 thousand rubles, respectively. The total predictive value of costs per 1 patient with ACS using the test was 32% lower than in the routine use of ticagrelor in all patients.

Conclusion. Assessment of platelets reactivity using VerifyNow P2Y12 assay in patients with ACS and modification of antithrombotic therapy in accordance with the received data can be considered as a cost-effective intervention which can reduce treatment costs as compared with the routine use of new antithrombotic drugs.

1. National guidelines on the diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation. Kardiovaskulyarnaya Terapiya i Profilaktika 2007; 6 (8) suppl 1: 1-28. Russian (Национальные рекомендации по диагностике и лечению больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Кардиоваскулярная терапия и профилактика 2007;6 (8) Приложение 1: 1-28).

2. National guidelines for the treatment of acute coronary syndromes without ST-segment elevation. Kardiovaskulyarnaya Terapiya i Profilaktika 2006; 8 (5) suppl 1: 1-34. Russian (Национальные рекомендации по лечению острого коронарного синдрома без стойкого подъема ST на ЭКГ. Кардиоваскулярная терапия и профилактика 2006; 8 (5) Приложение 1: 1-34).

3. Aradi D., Komosi A., Vorobcsuk A., et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160:543-51.

4. Brar S., ten Berg J., Marcucci R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54.

5. Combescure С., Fontana P., Mallouk N., et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(5): 923-33.

6. Reny J.-L., Fontana P., Hochholzer W., et al. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of major adverse cardiovascular events in patients on clopidogrel: Systematic review and collaborative meta-analysis of individual patient data. Circulation 2014; 130: A19827.

7. Gurbel P., Bliden K., Butler K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND Study. Circulation 2010; 121: 1188-99.

8. Wallentin L., Becker R., Budaj A. et al. for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.

9. Storey R., Becker R., Harrington R., et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011; 32: 2945-53.

10. Bonello L., Tantry U., Marcucci R., et al. Consensus and future directions on the definition of high ontreatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-33.

11. Fileti L., Campo G., Valgimigli M. Latest clinical data on testing for high on-treatment platelet reactivity. Rev Cardiovasc Med 2011; 12: S14-S22.

12. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-83.

13. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-42.

14. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.

15. Crespin D.J., Federspiel J.J., Biddle A.K, et al. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health 2011;14: 483-91.

16. Greenhalgh J., Bagust A., Boland A., et al. Ticagrelor for the treatment of acute coronary syndromes: A single technology appraisal. Liverpool: LRiG, University of Liverpool; 2011.

17. Life tables for WHO Member States. Russian Federation. 2012. Available at: http://www.who.int/healthinfo/paper09.pdf. Retrieved 08/12/2015.

18. Rudakova AV, Parfenov VA. Pharmacoeconomic aspects of prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: the use of apixaban compared with warfarin and acetylsalicylic acid. Ration Pharmacother Cardiol 2014; 10 (3): 275-82. Russian (Рудакова А.В., Парфенов В.А. Фармакоэкономические аспекты профилактики инсульта и системной тромбоэмболии у пациентов с неклапанной фибрилляцией предсердий: применение апиксабана по сравнению с варфарином и ацетилсалициловой кислотой. Рациональная Фармакотерапия в Кардиологии 2014; 10 (3): 275-82).

19. Secrieru EM, Moravian SV, Zakharova AB. Some features of formation of a hundred-hospital morbidity statistics according to federal reports. Social Aspects of Health of the Population in 2009; (3). Available at: http://vestnik.mednet.ru/content/view/130/30/lang,ru/. Retrieved 08/12/2015. Russian (Секриеру Е.М., Моравская С.В., Захарова А.Б. Некоторые особенности формирования статистики госпитальной заболеваемости по данным федеральной отчетности. Социальные Аспекты Здоровья Населения 2009; (3). Доступно на: http://vestnik.mednet.ru/content/view/130/30/lang,ru/. Проверено 12.08.2015).

20. Applications to the General Agreement on Tariffs tariff for medical care (medical services) and the terms of payment for medical care provided in the framework of the existing Territorial program of compulsory health insurance for citizens of the Russian Federation in St. Petersburg in 2014. Available at: http://www.spboms.ru/kiop/main?page_id=338. Retrieved 08/12/2015. Russian (Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2014 г. Доступно на: http://www.spboms.ru/kiop/main?page_id=338. Проверено 12.08.2015).

21. Tengs T.O., Lin T.H. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003; 21: 191-200.

22. Coleman C., Limone B. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Am J Cardiol 2013;112(3):355-62.

23. World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization; 2001.

24. Collet J.-P., Cayla G., Elhabad S. et al. for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-9.

25. Moiseev SV. The evolution of antiplatelet therapy: yesterday, today and tomorrow. Klinicheskaya Farmakologiya i Terapiya 2013; 22 (3): 12-9. Russian (Моисеев С.В. Эволюция антитромбоцитарной терапии: вчера, сегодня и завтра. Клиническая Фармакология и Терапия 2013; 22 (3): 12-9).